x
Filter:
Filters applied
- ACMG Statements and Guidelines
- Down syndromeRemove Down syndrome filter
- Noninvasive prenatal screeningRemove Noninvasive prenatal screening filter
- 2021 - 2023Remove 2021 - 2023 filter
ACMG Statements and Guidelines
These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.
2 Results
- ACMG Practice Guideline
Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)
Genetics in MedicineVol. 25Issue 2100336Published online: December 16, 2022- Jeffrey S. Dungan
- Susan Klugman
- Sandra Darilek
- Jennifer Malinowski
- Yassmine M.N. Akkari
- Kristin G. Monaghan
- and others
Cited in Scopus: 3This workgroup aimed to develop an evidence-based clinical practice guideline for the use of noninvasive prenatal screening (NIPS) for pregnant individuals at general risk for fetal trisomy 21, trisomy 18, or trisomy 13 and to evaluate the utility of NIPS for other chromosomal disorders. - ACMG Systematic Evidence Review
Systematic evidence-based review: The application of noninvasive prenatal screening using cell-free DNA in general-risk pregnancies
Genetics in MedicineVol. 24Issue 7p1379–1391Published online: May 24, 2022- Nancy C. Rose
- Elizabeth S. Barrie
- Jennifer Malinowski
- Gabrielle P. Jenkins
- Monica R. McClain
- Danielle LaGrave
- and others
Cited in Scopus: 7Noninvasive prenatal screening (NIPS) using cell-free DNA has been assimilated into prenatal care. Prior studies examined clinical validity and technical performance in high-risk populations. This systematic evidence review evaluates NIPS performance in a general-risk population.